156 results about "Medications treatments" patented technology

Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown to induce a rapid onset of antipsychotic action and increase the number of responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic.

The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.

The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type n diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.

A system and apparatus for accurate and secure dispensing of products using an automated dispensing machine, and transmission, processing and analysis of data concerning items dispensed. In one embodiment the system provides the possibility of combined pharmaceutical supply chain management and medication treatment compliance management and may be applied to controlled dispensing of medications, enabling incentives to encourage higher compliance, recording and processing of patient and health care data. The system allows for automatic replenishment of medications to the RFID equipped medication storage enclosure at the healthcare site. It also allows for complete logging of data relating to which patient has received the correct dosage at what time, by whom this medication was administered, and correlation with other possible RFID tagged documents.

The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tctrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.

The invention relates to a medicament for treating cerebral infarction. A preparation method comprises the following steps: using gingko leaves, hawthorn leaves, angelica, rhizoma gastrodiae, caulis milletiae, sweetgum fruit, earthworm, uncaria, clematis root, dried orange peel and licorice as raw material drugs, adding water into the raw material drugs and decocting the mixture, condensing the decoction to be thick paste, drying and crushing the thick paste into medicinal powder, filling the medicinal powder into capsules, sterilizing and disinfecting the capsules to obtain the capsule preparation. The medicament treats both symptoms and root causes during cerebral infarction treatment, has the characteristics of definite effect and quick healing, has no toxic and side effect or allergic reaction, uses little amount of medicament, has low cost, has obvious effect on acute cerebral infarction, can also control disease development of chronic cerebral infarction, and is easy to be accepted by patients. The cure rate for treating the acute cerebral infarction is 96 percent, and the cure rate for treating the chronic cerebral infarction is 93 percent.

The present invention relates generally to the use of vitamin B12 (cobalamin or cyanocobalamin) alone or in combination with other photoprotective agents, including specifically other vitamins such as vitamin B9 (folic acid or folate) and vitamin B3 (niacin or niacinamide), or any chemical derivative of these vitamins and their salts, as a filter to protect cells against the damaging effects of ultraviolet (UV) light. The invention is, in one aspect, a method of reducing the rate of UV damage to cells exposed to a UV light source, by treating the cells with the vitamin composition, either alone or in combination with other photoprotective agents. Other aspects of the invention are compositions comprising effective amounts of vitamin B12 alone or in combination with other photoprotective agents including vitamin B9 and vitamin B3 and a pharmaceutically-acceptable carrier, that are useful in protecting cells, particularly skin cells, against the burning, genotoxic (mutagenic and carcinogenic), immunosuppressive and photoaging effects of UV light, especially sunlight. The invention has application as a UV light filter in oral preparations including tablets and drinks, topical creams, lotions, sprays, wipes and cosmetics. The invention also has application as a medicinal treatment for dermatological conditions caused by exposure to sunlight, such as actinic keratoses, photodermatitis, photo-induced (discoid) lupus erythematosus and the photosensitizing effects of a variety of drugs used commonly in clinical practice (e.g. certain antihistamines, ACE inhibitors, and antibiotics such as tetracycline).

The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.

The invention discloses application of a fibroblast growth factor-21 mature peptide in preparation of hepatic fibrosis treatment and/or prevention drugs. The invention also discloses a medicine for treating and/or preventing hepatic fibrosis, and the active ingredient of the medicine refers to the fibroblast growth factor-21 mature peptide. The fibroblast growth factor-21 mature peptide can effectively inhibit hepatic fibrosis, can serve as a medicine for treating and/or preventing hepatic fibrosis and has significant values for treating and/or preventing hepatic fibrosis.

The invention discloses a small-grain high-Si Y-type molecular sieve and a preparation method thereof. The small-grain high-Si Y-type molecular sieve is a product prepared by using a small-grain NaY molecular sieve as a raw material and selecting proper modification processes, namely ammonia exchange, ammonium hexfluorosilicate for dealuminzation and silicon supplement, hydro-thermal treatment and aluminum salt aqueous solution treatment. The small-grain NaY molecular sieve used by the method can guarantee the skeleton continuity of the molecular sieve product, reduce the collapse possibilityof skeleton structure and maximally retain the integrity of Si-Al-O structure of the product during the subsequent medication treatments due to the high thermal and hydrothermal stabilities, high Si-Al ratio, high stability and uniform skeleton Si-Al structure; therefore, the product still has a crystalline retention degree as high as above 95 percent while having the greatly improved Si-Al ratio. The Y-type molecular sieve can be used as the active component for the hydrocracking catalysts to improve the activities of the catalysts, selectivity of the target product and the quality of the product.

A pharmaceutical composition and dosage form for the treatment of incontinence with oxybutynin and a second drug is provided. The second drug can be darifenacin or tolterodine. Depending upon the route of administration, the dosage form used, and the second drug used, the dosage form may independently include therapeutic or sub-therapeutic amounts of the oxybutynin and the second drug. Particular embodiments include a dosage form that provides a controlled release of oxybutynin and the second drug to maintain therapeutically effective levels oxybutynin and/or the second in a mammal for an extended period of time. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. A method of treating urinary (stress or urge) incontinence with the pharmaceutical composition and dosage form is provided. Together, oxybutynin and the second drug provide an overall improved therapeutic benefit over either agent alone when administered at approximately the same dose.

The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.

The invention relates to an intelligent ultrasonic diagnosis and treating instrument and an application method of the intelligent ultrasonic diagnosis and treating instrument. The intelligent ultrasonic diagnosis and treating instrument comprises an information collection and transmission system, an expert knowledge database, a recipe database, a data storage server, a man-machine conversation system, an ultrasonic medication system and an intelligent analysis and conversion system, wherein the intelligent analysis and conversion system is respectively connected with each of other systems, the information collection and transmission system can collect, measure and transmit relevant data information required for making an ultrasonic medication treatment scheme, the ultrasonic medication treatment scheme is obtained and automatically generated, the ultrasonic medication treatment is executed, the relevant data information during ultrasonic medication is measured and transmitted in real time, and the optimal ultrasonic medication treatment scheme is obtained through cyclic measurement. Through integrating two parts of function modules including a diagnosis function module and a treatment function module, the diagnosis and treatment integration and intellectualization are realized, and in addition, the precise guide and the intellectualization of the treatment process control are realized.

The present invention discloses an oral administration Chinese traditional medicine combination for treating hypertension which belongs to the Chinese traditional medicine field. The Oral administration Chinese traditional medicine combination for treating hypertension comprise haw, Salvia miltiorrhiza, Concha haliotidis, wild chrysanthemum, Prunella vulgaris, mistletoe, radix-polygoni multiflori, uncaria, kudzu, eucommia bark, aweto and liquorices according to certain weight. Impurity of all raw material medicines is removed, and then the medicines are decocted by water, with one dosage per day, and ten days as a course of treatment. The medicine of the invention for treating hypertension disease has exact hypotensive effect, long curative effect, no toxic and side effects and uneasy recurrence.

A system and method for increasing patient adherence to following medication treatment regimens. An adherence data processing and communication system generates and displays medication adherence data based on historical medication information. The system is linked to other systems involved with electronic ordering and filling of prescriptions, such as electronic prescription and pharmacy systems all connected by suitable wired and/or wireless communication protocols including the Internet. In one embodiment, the adherence data is displayed in the form of an interactive report card which provides a user with adherence metrics in both summary and more detailed formats for prescription medications taken by the patient. A related method executed by the data processing and communication system is disclosed.

The invention relates to 1,2,5-trisubstituted 1,2-dihydroindazol-3-ones of formula (I)whereinX is -SO2-, -SO-, -(CH2)p-, -(CH2)p-O-, -(CH2)p-(C=O)-, -(CH2)p-(C=O)-NH-, -(CH2)p-CHOH-, -CHOH-(CH2)p-, -(CH2)p-CH=CH-, -CH=CH-(CH2)p-,Y is -(C=O)-, -(C=O)-NH-, -(C=O)-NH-(CH2)p-, -C=O)-(CH2)p-, -(CH2)p-, -(CH2)p-O-, -(CH2)p-(C=O)-, -(CH2)p-(C=O)-NH-, -(CH2)p-(C=O)-NH-(CH2)p-, -(CH2)p-CHOH-, -CHOH-(CH2)p-, -(CH2)p-CH=CH-, -CH=CH-(CH2)p-,Z is -O-, -O-(CH2)p-, -NH-, -NH-(C=O)-, -NH-(C=O)-NH-, -NH-(C=O)-O-, -NH-CH2-(C=O)- and -NH-(C=O)-CH2-,P is a cardinal number from 1 to 4,R1, R2 and R3 can be the same or different and are:mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles having from 5 to 14 ring members; or mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles having from 5 to 15 ring members and from 1 to 6 heteroatoms,in which the carbocycles and the heterocycles can be mono- or polysubstituted by:C1-6-alkyl, -O-C1-6-alkyl, -O-C3-7-cycloalkyl, mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles having from 3 to 14 ring members, mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles having from 5 to 15 ring members and from 1 to 6 heteroatoms,R1 is also H, provided that when X is CH2, then R1 is not H,R3-Z is also NO2,and their pharmaceutically acceptable salts,but excluding compounds of formula (I) in whichif Z is -NH-(C=O)-, -NH-(C=O)-NH-, -NH-(C=O)-O-, -NH-(C=O)-CH2 and at the same time R1 is phenyl, monosubstituted or polysubstituted by -COOH, -COOC1-6-alkyl, -(CH2)p-COOH, -(CH2)p-COOC1-6-alkyl -CONHC1-6-alkyl, -CONHC6-14-aryl, -CONHSO2C1-6-alkyl, -CONHSO2C6-4-aryl, 1H-tetrazol-5-yl, then R2 is not phenyl, monosubstituted or polysubstituted by CN, halogen, C1-4-alkyl, C1-4-alkyloxy, CF3; andif R3-Z is NO2, then R1-X is not benzyl or 4-methoxybenzyl, and R2-Y is not benzyl or 2-picolyl at the same time; and to pharmaceutical treatment processes, and processes for making.